| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911029 | Lung Cancer | 2013 | 7 Pages |
Abstract
These data suggest that EGFR IHC does not have value as a marker to predict erlotinib benefit in the first-line maintenance setting for advanced NSCLC.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Julien Mazières, Wolfram Brugger, Federico Cappuzzo, Peter Middel, Alice Frosch, Ilze Bara, Gaelle Klingelschmitt, Barbara Klughammer,